2.3. Randomization, Allocation, and Intervention
cardiotoxic
Randomization was on a 1:1 ratio to receive ivabradine or standard care (the observation during cardiotoxic treatment with anthracyclines). No placebo was used in this study. The randomization was performed by a computer-based randomization list generated using GraphPad by Dotmatics Prism program. Randomization and allocation data were maintained by an independent research coordinator. A blinded investigator performed all echocardiograms.The initial dose of ivabradine was 5 mg twice daily, subsequently adjusted according to the heart rate. Ivabradine was continued until completion of anthracycline chemotherapy.